EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Considerations on the use of different comparators in pharmacovigilance: A methodological review

Christopher A Gravel, Antonios Douros iD

British Journal of Clinical Pharmacology · 2023-09 · 89 (9) · 2671-2676

DOI: 10.1111/bcp.15802 ↗

At a glance

Übersichtsarbeit in British Journal of Clinical Pharmacology, published online on 2023-06-08. Written by Christopher A Gravel and 1 co-authors. Institution: School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada. Major MEDLINE topics: Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Cited 55 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pharmacovigilance studies based on spontaneous reporting systems use disproportionality analysis methods to identify drug‐event combinations with higher‐than‐expected reporting. Enhanced reporting is deemed as a proxy for a detected signal and is used to generate drug safety hypotheses, which can then be tested in pharmacoepidemiologic studies or randomized controlled trials. Higher‐than‐expected reporting means that the reporting rate of a drug‐event combination of interest is disproportionately higher than the rate in a specific comparator or reference set. Currently, it is unclear which comparator is the most appropriate for use in pharmacovigilance. Moreover, it is also unclear how the selection of a comparator may affect the directionality of the various reporting and other biases. This paper reviews commonly used comparators chosen for signal detection studies (active comparator, class‐exclusion comparator, and full data reference set). We give an overview of the advantages and disadvantages of each method based on examples from the literature. We also touch upon the challenges related to the derivation of general recommendations for the selection of comparators when mining spontaneous reports for pharmacovigilance.

Subjects

MeSH terms (MEDLINE)

PharmacovigilanceDrug-Related Side Effects and Adverse ReactionsHumansAdverse Drug Reaction Reporting SystemsDatabases, Factual

Author keywords

disproportionality analysesdrug safetypharmacovigilancespontaneous reports

Authors and institutions

  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada.
  • Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.
  • Department of Medicine, McGill University, Montreal, Canada.
  • Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Canada.
  • Institute of Clinical Pharmacology and Toxicology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

ORCID profiles: Antonios Douros

Cite

APA

Gravel, C. A., & Douros, A. (2023). Considerations on the use of different comparators in pharmacovigilance: A methodological review. British Journal of Clinical Pharmacology, 89(9), 2671-2676. https://doi.org/10.1111/bcp.15802

Vancouver

Gravel CA, Douros A. Considerations on the use of different comparators in pharmacovigilance: A methodological review. British Journal of Clinical Pharmacology. 2023;89(9):2671-2676. doi:10.1111/bcp.15802

BibTeX
@article{Gravel2023,
  author = {Gravel, Christopher A and Douros, Antonios},
  title = {Considerations on the use of different comparators in pharmacovigilance: A methodological review},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {9},
  pages = {2671--2676},
  doi = {10.1111/bcp.15802}
}
Start for free →